Update date
22 Nov 2022
Biotech Acquisition Co financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2022.
- Location
- New York, NY
- Fiscal year end
- 31 December
- Latest financial report
- 22 Nov 2022
Shareable Research Card
Biotech Acquisition Co Financial Facts
Biotech Acquisition Co has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q3 2022
- Latest reported value
- Return On Equity -67%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2022
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2022.
- Most recent SEC facts end date on this page: 30 Sep 2022.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Biotech Acquisition Co
Latest financial period: Q3 2022. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q3 2022
SEC-backed company facts were refreshed from filings filed on 22 Nov 2022.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 98% versus the comparable prior period.
Compared with
Compared with Biotech Acquisition Co's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2022.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- Biotech Acquisition Co financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q3 2022.
- Headline metric: Return On Equity -67%.
Change
- Return On Equity YoY change: -98%.
- Most recent SEC facts end date: 30 Sep 2022.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
See Original Filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2022-09-30) highlights Return On Equity -66.6%, Return On Assets 4.8%, and Current Ratio 0.03x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
8.0/100
Weak Confidence low
Return On Equity
-67%
Metric score 0.0/100
Return On Assets
4.8%
Metric score 34.4/100
Financial Health
- Current Ratio
- 0.03x
- Debt to Equity
- -1.01x
Strengths
No strong signals yet.
Watchpoints
Return On Equity, Return On Assets, and Current Ratio
Key metrics snapshot
Return On Equity
-67%
YoY: -98%
Return On Assets
4.8%
YoY: -533%
Current Ratio
0.03x
YoY: -99%
Debt-to-equity
-1.01x
YoY: -36%
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -67% | -98% |
| Return On Assets | 4.8% | -533% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 0.03x | -99% |
| Debt-to-equity | -1.01x | -36% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| Net Income (Loss) Attributable to Parent | $10,983,949 |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Common Stock, Value, Issued | $575 | 0% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY change |
|---|---|---|
| Assets | $231,389,235 | +0.3% |
| Assets, Current | $95,252 | -86% |
| Cash and Cash Equivalents, at Carrying Value | $13,145 | -97% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $13,145 | -97% |
| Liabilities | $13,215,210 | -36% |
| Liabilities and Equity | $231,389,235 | +0.3% |
| Liabilities, Current | $3,517,792 | +881% |
| Operating Income (Loss) | $4,363,031 | -4831% |
| Preferred Stock, Par or Stated Value Per Share | 0 | 0% |
| Preferred Stock, Shares Authorized | 5,000,000 | 0% |
| Retained Earnings (Accumulated Deficit) | $13,120,533 | +34% |
| Stockholders' Equity Attributable to Parent | $13,119,958 | +34% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first